BACKGROUND: Previous studies suggest that obesity is associated with higher prostate cancer progression and mortality despite an association with lower prostate cancer incidence. This study aims to better understand these apparently inconsistent relationships among obese men by combining evidence from 3 nationally representative cross-sectional surveys. METHODS: We evaluated relationships between obesity and 1) testosterone concentrations in the Third National Health and Nutrition Examination Survey (NHANES III; n=845); 2) prostate-specific antigen (PSA) in NHANES 2001-2004 (n=2458); and 3) prostate biopsy rates in the National Health Interview Survey (NHIS 2000; n=4789) population. Mean testosterone, PSA concentrations, and biopsy rates were computed for Body Mass Index (BMI) categories. RESULTS: Testosterone concentrations were inversely associated with obesity (P-trend <.0001) in NHANES III. In NHANES 2001-2004, obese (BMI >35) versus lean (BMI <25) men were less likely to have PSA concentrations that reached the biopsy threshold of >4 ng/mL (3% vs 8%; P <.0001). Among NHIS participants, all BMI groups had similar rates of PSA testing (P=.24). However, among men who had PSA tests, 11% of men with BMI >30 versus 16% with BMI <25, achieved a PSA threshold of 4 ng/mL; P=.01. Furthermore, biopsy rates were lower among men with BMI >30 versus BMI <25 in NHIS participants (4.6% vs 5.8%; P=.05). CONCLUSIONS: Obesity was associated with lower PSA-driven biopsy rates. These data support further studies to test the hypothesis that obesity affects prostate cancer detection independent of prostate cancer risk by decreasing the PSA-driven biopsy rates.
BACKGROUND: Previous studies suggest that obesity is associated with higher prostate cancer progression and mortality despite an association with lower prostate cancer incidence. This study aims to better understand these apparently inconsistent relationships among obesemen by combining evidence from 3 nationally representative cross-sectional surveys. METHODS: We evaluated relationships between obesity and 1) testosterone concentrations in the Third National Health and Nutrition Examination Survey (NHANES III; n=845); 2) prostate-specific antigen (PSA) in NHANES 2001-2004 (n=2458); and 3) prostate biopsy rates in the National Health Interview Survey (NHIS 2000; n=4789) population. Mean testosterone, PSA concentrations, and biopsy rates were computed for Body Mass Index (BMI) categories. RESULTS:Testosterone concentrations were inversely associated with obesity (P-trend <.0001) in NHANES III. In NHANES 2001-2004, obese (BMI >35) versus lean (BMI <25) men were less likely to have PSA concentrations that reached the biopsy threshold of >4 ng/mL (3% vs 8%; P <.0001). Among NHIS participants, all BMI groups had similar rates of PSA testing (P=.24). However, among men who had PSA tests, 11% of men with BMI >30 versus 16% with BMI <25, achieved a PSA threshold of 4 ng/mL; P=.01. Furthermore, biopsy rates were lower among men with BMI >30 versus BMI <25 in NHIS participants (4.6% vs 5.8%; P=.05). CONCLUSIONS:Obesity was associated with lower PSA-driven biopsy rates. These data support further studies to test the hypothesis that obesity affects prostate cancer detection independent of prostate cancer risk by decreasing the PSA-driven biopsy rates.
Authors: Grace Lu-Yao; Peter C Albertsen; Janet L Stanford; Therese A Stukel; Elizabeth S Walker-Corkery; Michael J Barry Journal: BMJ Date: 2002-10-05
Authors: S O Andersson; A Wolk; R Bergström; H O Adami; G Engholm; A Englund; O Nyrén Journal: J Natl Cancer Inst Date: 1997-03-05 Impact factor: 13.506
Authors: Edward Giovannucci; Eric B Rimm; Yan Liu; Michael Leitzmann; Kana Wu; Meir J Stampfer; Walter C Willett Journal: J Natl Cancer Inst Date: 2003-08-20 Impact factor: 13.506
Authors: Stephen J Freedland; William J Aronson; Christopher J Kane; Joseph C Presti; Christopher L Amling; David Elashoff; Martha K Terris Journal: J Clin Oncol Date: 2003-12-22 Impact factor: 44.544
Authors: Robert J MacInnis; Dallas R English; Dorota M Gertig; John L Hopper; Graham G Giles Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-12 Impact factor: 4.254
Authors: Ian M Thompson; Donna K Pauler; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Howard L Parnes; Lori M Minasian; Leslie G Ford; Scott M Lippman; E David Crawford; John J Crowley; Charles A Coltman Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245
Authors: D I Chu; C De Nunzio; L Gerber; J-A Thomas; E E Calloway; S Albisinni; C Senocak; M G McKeever; D M Moreira; A Tubaro; J W Moul; S J Freedland; L L Bañez Journal: Prostate Cancer Prostatic Dis Date: 2011-07-05 Impact factor: 5.554
Authors: Wendy E Barrington; Jeannette M Schenk; Ruth Etzioni; Kathryn B Arnold; Marian L Neuhouser; Ian M Thompson; M Scott Lucia; Alan R Kristal Journal: JAMA Oncol Date: 2015-06 Impact factor: 31.777
Authors: A S Parker; D D Thiel; E Bergstralh; R E Carlson; L J Rangel; R W Joseph; N Diehl; R J Karnes Journal: Prostate Cancer Prostatic Dis Date: 2013-08-20 Impact factor: 5.554